Meeting highlights from: 47th Annual Meeting of the American Society of Hematology December 2005, Atlanta, GA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use / Q000633:toxicity; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006405:Hematology / Q000639:trends*; D006801:Humans; D006877:Hydroxamic Acids / Q000633:toxicity; D007211:Indoles; D008223:Lymphoma / Q000188:drug therapy*; D000077767:Panobinostat; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D006877:Hydroxamic Acids; D007211:Indoles; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D000077767:Panobinostat; D011241:Prednisone